A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

计划入组 172 人 · 首次发布于 2022 年 12 月 13 日

PrP-targeting siRNA Safety & Mechanism Study

计划入组 30 人 · 首次发布于 2026 年 3 月 3 日

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

计划入组 40 人 · 首次发布于 2023 年 5 月 6 日

PNPLA3 siRNA therapy (NASH)

PNPLA3

ARO-PNPLA3

Vir Biotechnology

United States

University of Siena

Italy

Mirna Therapeutics, Inc.

United States

Evolving Landscape of MASLD: New Insights and Therapeutic Approaches

Wave Life Sciences Advances Obesity and Cardiometabolic Programs with RNA Therapies

Wave Life Sciences Reports Dose-Dependent Activin E Reductions Up to 85% with WVE-007 in Obesity Trial